Crisaborole Topical Ointment, 2%, a novel nonsteroidal, anti-inflammatory, topical, phosphodiesterase 4 inhibitor, reduced pruritus and signs of atopic dermatitis in 2 phase 3 studies in children and adults with mild-to-moderate atopic dermatitis

被引：0
|
作者：
Zane, Lee Thomas [1 ]
Hebert, Adelaide A. [2 ]
Eichenfield, Lawrence F. [3 ,4 ]
Lebwohl, Mark G. [5 ]
Paller, Amy S. [6 ]
Simpson, Eric L. [7 ]
Tom, Wynnis L. [3 ,4 ]
Hughes, Matty H. [1 ]
机构：
[1] Anacor Pharmaceut Inc, Palo Alto, CA USA
[2] Univ Texas Hlth Sci Ctr Houston, Houston, TX 77030 USA
[3] Rady Childrens Hosp, San Diego, CA USA
[4] Univ Calif San Diego, San Diego, CA 92103 USA
[5] Icahn Sch Med Mt Sinai, New York, NY 10029 USA
[6] Northwestern Univ, Feinberg Sch Med, Evanston, IL 60208 USA
[7] Oregon Hlth & Sci Univ, Portland, OR 97201 USA
来源：
JOURNAL OF IMMUNOLOGY | 2016年 / 196卷
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
引用
收藏
页数：2
相关论文
共 50 条
  • [1] A Novel Nonsteroidal, Topical Anti-inflammatory, Phosphodiesterase 4 Inhibitor, Crisaborole Ointment, Reduced Pruritus and Signs of Atopic Dermatitis in 2 Phase 3 Studies in Children and Adults
    Hebert, Adelaide A.
    Eichenfield, Lawrence F.
    Lebwohl, Mark G.
    Paller, Amy S.
    Simpson, Eric L.
    Tom, Wynnis L.
    Hughes, Matilda H.
    Zane, Lee T.
    PEDIATRICS, 2018, 141
  • [2] Efficacy and Safety of Crisaborole Topical Ointment, 2%, a Novel, Nonsteroidal, Topical, Anti-Inflammatory, Phosphodiesterase Inhibitor in 2 Phase 3 Studies in Children and Adults with Mild-to-Moderate Atopic Dermatitis
    Boguniewicz, Mark
    Paller, Amy S.
    Tom, Wynnis L.
    Lebwohl, Mark G.
    Blumenthal, Robin L.
    Call, Robert S.
    Eichenfield, Lawrence F.
    Forsha, Douglass W.
    Rees, William C.
    Simpson, Eric L.
    Gold, Linda F. Stein
    Zaenglein, Andrea L.
    Hughes, Matty H.
    Zane, Lee T.
    Hebert, Adelaide A.
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2016, 137 (02) : AB397 - AB397
  • [3] A novel, nonsteroidal, topical, anti-inflammatory, phosphodiesterase inhibitor, Crisaborole Topical Ointment, 2%, in two phase 3 studies in children and adults with mild to moderate atopic dermatitis
    Paller, A. S.
    Tom, W. L.
    Call, R. S.
    Eichenfield, L.
    Forsha, D.
    Rees, W.
    Spellman, M.
    Zane, L. T.
    Hebert, A. A.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2016, 136 (09) : S166 - S166
  • [4] Two phase 3 study results of children and adults with mild-to-moderate atopic dermatitis treated with Crisaborole Topical Ointment, 2%, a novel, nonsteroidal, topical, anti-inflammatory, phosphodiesterase 4 inhibitor
    Zane, Lee Thomas
    Paller, Amy S.
    Tom, Wynnis L.
    Lebwohl, Mark G.
    Blumenthal, Robin L.
    Boguniewicz, Mark
    Call, Robert S.
    Eichenfield, Lawrence F.
    Forsha, Douglass W.
    Rees, William C.
    Simpson, Eric L.
    Gold, Linda F. Stein
    Zaenglein, Andrea L.
    Hebert, Adelaide A.
    JOURNAL OF IMMUNOLOGY, 2016, 196
  • [5] Phase 3 Studies Treating Children and Adult Patients with Mild to Moderate Atopic Dermatitis with Crisaborole Ointment, a Novel, Nonsteroidal, Topical Anti-inflammatory, Phosphodiesterase 4 Inhibitor
    PaIler, Amy S.
    Tom, Wynnis L.
    Lebwohl, Mark G.
    Boguniewicz, Mark
    Eichenfield, Lawrence F.
    Forsha, Douglass W.
    Call, Robert S.
    Rees, William C.
    Zane, Lee T.
    Hebert, Adelaide A.
    PEDIATRICS, 2018, 141
  • [6] Reduced pruritus and signs of atopic dermatitis in phase 3 trials with a nonsteroidal topical phosphodiesterase inhibitor, crisaborole
    Hebert, A. A.
    Eichenfield, L.
    Lebwohl, M. G.
    Paller, A. S.
    Simpson, E. L.
    Tom, W. L.
    Zane, L. T.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2016, 136 (05) : S49 - S49
  • [7] Crisaborole Topical Ointment, 2%: A Nonsteroidal, Topical, Anti-Inflammatory Phosphodiesterase 4 Inhibitor in Clinical Development for the Treatment of Atopic Dermatitis
    Jarnagin, Kurt
    Chanda, Sanjay
    Coronado, Dina
    Ciaravino, Vic
    Zane, Lee T.
    Guttman-Yassky, Emma
    Lebwohl, Mark G.
    JOURNAL OF DRUGS IN DERMATOLOGY, 2016, 15 (04) : 390 - 396
  • [8] 2% Crisaborole topical ointment for the treatment of mild-to-moderate atopic dermatitis
    Cheape, Alice C.
    Murrell, Dedee F.
    EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2017, 13 (05) : 415 - 423
  • [9] Long-term Safety of Crisaborole, a Novel, Nonsteroidal, Topical, Anti-inflammatory, Phosphodiesterase 4 Inhibitor in Children and Adults with Mild to Moderate Atopic Dermatitis
    Eichenfield, Lawrence F.
    Call, Robert S.
    Forsha, Douglass W.
    Fowler, Joseph
    Hebert, Adelaide A.
    Spellman, Mary
    Gold, Linda F. Stein
    Van Syoc, Merrie
    Zane, Lee T.
    Tschen, Eduardo
    PEDIATRICS, 2018, 141
  • [10] Phase 3 studies in atopic dermatitis with the novel, nonsteroidal topical phosphodiesterase 4 inhibitor, crisaborole
    Paller, A. S.
    Tom, W. L.
    Call, R. S.
    Eichenfield, L.
    Forsha, D.
    Rees, W. C.
    Zane, L. T.
    Hebert, A. A.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2016, 136 (05) : S50 - S50
12345